Martin H. Jr. Huber Sells 829 Shares of TESARO Inc (TSRO) Stock
TESARO Inc (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
TESARO Inc (NASDAQ:TSRO) traded down $0.22 on Thursday, reaching $84.76. The company had a trading volume of 588,300 shares, compared to its average volume of 1,019,860. TESARO Inc has a 12-month low of $79.03 and a 12-month high of $192.94. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. During the same period in the previous year, the company earned ($1.72) EPS. The company’s revenue for the quarter was up 740.3% on a year-over-year basis. equities analysts expect that TESARO Inc will post -8.17 earnings per share for the current year.
A number of brokerages have commented on TSRO. Credit Suisse Group set a $190.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. Morgan Stanley restated an “overweight” rating and set a $183.00 price objective on shares of TESARO in a research report on Thursday, August 10th. HC Wainwright restated a “buy” rating and set a $158.00 price objective on shares of TESARO in a research report on Monday, November 20th. Evercore ISI began coverage on TESARO in a research report on Wednesday, August 16th. They set an “in-line” rating and a $121.00 price objective for the company. Finally, SunTrust Banks restated a “buy” rating and set a $160.00 price objective on shares of TESARO in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $159.39.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its position in TESARO by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 90,684 shares of the biopharmaceutical company’s stock worth $13,954,000 after buying an additional 363 shares during the period. Capstone Asset Management Co. bought a new position in TESARO in the 2nd quarter worth approximately $238,000. Bank of Montreal Can increased its position in TESARO by 156.5% in the 2nd quarter. Bank of Montreal Can now owns 5,863 shares of the biopharmaceutical company’s stock worth $820,000 after buying an additional 3,577 shares during the period. Aperio Group LLC increased its position in TESARO by 4.5% in the 2nd quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock worth $512,000 after buying an additional 156 shares during the period. Finally, Sumitomo Mitsui Asset Management Company LTD bought a new position in TESARO in the 2nd quarter worth approximately $354,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.